Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from ...

Russia may face a new wave of drugs’ shortages, particularly those, which are used for the treatment of rare diseases, as ...

AbbVie, Danaher, Thermo Fisher Scientific, Cognizant Technology Solutions, Vertex Pharmaceuticals, Alnylam Pharmaceuticals, ...

The analyst also expected major growth opportunities, including the launch of Alyftrek, which could convert many Trikafta therapy patients, and key drug trial results from Novartis and Bristol ...

We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...

It is also dosed just once a day, while Trikafta needs twice-daily dosing. The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from ...

It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.

Individual researchers and university leaders need to make the case for science to their elected representatives and to the public at large.